Disc Medicine

1. Bitopertin filingBy year-end 2026Bitopertin filing, By year-end 2026, notable
2. Bitopertin topline4Q 2026Bitopertin topline, 4Q 2026, thesis-defining
3. Selcodebart Ph2 readout4Q 2026Selcodebart Ph2 readout, 4Q 2026, notable
4. DISC-3405 Ph1 readout4Q 2026DISC-3405 Ph1 readout, 4Q 2026, notable
5. Disc Medicine corporate updateNov 2026Disc Medicine corporate update, Nov 2026, routine
6. Bitopertin corporate updateDec 17, 2026Bitopertin corporate update, Dec 17, 2026, routine
7. Pipeline multiple Ph3 readout2027Pipeline multiple Ph3 readout, 2027, notable
8. Selcodebart Ph3 start1H 2027Selcodebart Ph3 start, 1H 2027, routine
9. Dersimelagon LEO PDUFA dateFeb 2027Dersimelagon LEO PDUFA date, Feb 2027, material
10. Disc Medicine financingApr 30, 2027Disc Medicine financing, Apr 30, 2027, routine
11. Bitopertin FDA decisionMid-2027Bitopertin FDA decision, Mid-2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.